AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02408692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ECx2
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
Study NCT00838149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine
Description: Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Study NCT05434884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal veneer restorations
Description: occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars
Study NCT00838149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein
Description: Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Study NCT02984943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: 30 treatments of Hyperbaric Oxygen.
Study NCT02540889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory comprehension therapy.
Description: 100 hours of Auditory comprehension therapy embedded within a computer game.
Study NCT03229174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
Study NCT03229174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
Study NCT05434884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endocrown restorations
Description: endocrown restorations
Study NCT03268356 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AGN1 Femoral Local Osteo-Enhancement Procedure Kit
Description: A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
Study NCT03229174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (sugar pill)
Study NCT02280122 — intervention group
Intervention type: OTHER
Intervention: no intervention provided
Description: No Intervention was rendered but the aMMP-8 test was made
Study NCT00631878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
Study NCT02402725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: (1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
Study NCT03529071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKD-Question Prompt Sheet
Description: The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
Study NCT00088556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLK286
Description: Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
Study NCT00088556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 mg/mL/min Once every 3 weeks
Study NCT00631878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
Study NCT00088556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m² Once every 3 weeks
Study NCT02958683 — intervention group
Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
Study NCT01583478 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
Study NCT01246154 — intervention group
Intervention type: OTHER
Intervention: EXERCISE TRAINING
Description: EXERCISE TRAINING
Study NCT01565343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi)
Study NCT03823391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-3373
Description: ABBV-3373 is administered as intravenous (IV) infusion
Study NCT03823391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-3373
Description: Placebo for ABBV-3373 is administered as IV infusion
Study NCT03823391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab is administered as subcutaneous (SC) injection
Study NCT03823391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab is administered as subcutaneous (SC) injection
Study NCT03489733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Formula
Description: Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
Study NCT03489733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control formula
Description: Infant formula with intact proteins and pre- and probiotics.
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine 10mg
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine10mg /Valsartan 80mg
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10mg /Valsartan 160mg
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipin 10mg Placebo
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine10mg /Valsartan 80mg Placebo
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine10mg /Valsartan 80mg Placebo
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine 10mg /Valsartan 160mg Placebo
Study NCT01928628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10mg /Valsartan 160mg Placebo
Study NCT00254566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: 1 capsule once daily for 5 days
Study NCT00254566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 X 400mg capsule once daily for 5 days
Study NCT00254566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azithromycin SR Placebo
Description: single dose, oral.
Study NCT00254566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin SR
Description: single dose 2.0 g oral
Study NCT03913663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vestibuloocular training
Description: using vestibulo ocular training program for training neglect patient
Study NCT03913663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular exercise training for hemiplegic patients
Description: Traditional gait training program.
Study NCT02308644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal bevacizumab injection(1.25mg)
Description: intravitreal bevacizumab injection(1.25mg) / Sham injection
Study NCT02308644 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravitreal bevacizumab injection(1.25mg)
Description: intravitreal bevacizumab injection(1.25mg) / Sham injection
Study NCT03737656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring
Description: Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
Study NCT02144779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned to palliative care team
Description: Communication and Support through the palliative care team assigned to intervention participants.
Study NCT02144779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: usual hospital care, not assigned to palliative care team
Study NCT03052647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermaclip
Description: Dermaclip is an adhesive latch device used for skin closure
Study NCT03052647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular suture
Description: subcuticular suture will be used as the device to close the skin in this arm
Study NCT01279057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
Description: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
Study NCT01279057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray
Description: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
Study NCT01279057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Study NCT01695421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medium-frequency alternating current
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
Study NCT01695421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst-modulated alternating current
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
Study NCT02738671 — intervention group
Intervention type: OTHER
Intervention: olfactory function measurement
Study NCT01695421 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
Study NCT01695421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
Study NCT01354132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-acetylcysteine
Description: 900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
Study NCT04186182 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CICI - Feasibility trial study group
Description: The intervention will include 7 individualized meetings with the family (2 home visits + 5 videoconferences), 2 parent group sessions and 4 meetings with school and local care providers, delivered over a 4-5 month period.
Study NCT02967107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare polypectomy
Description: Use of a polypectomy snare closed over a polyp without electrocautery
Study NCT02967107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection
Description: Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
Study NCT02809469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban dose reduction
Description: Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
Study NCT03452501 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
Study NCT01270503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT04163289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
Study NCT01354132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are placed in water or juice in the AM and PM
Study NCT01068444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months
Study NCT01068444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30 mg/d for 6 months
Study NCT02313740 — intervention group
Intervention type: BIOLOGICAL
Intervention: Butantan Fragmented Inactivated Trivalent Influenza Vaccine
Description: Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
Study NCT01774214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-Pull technique
Description: Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model.
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study NCT01774214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disconnect-Reconnect Technique
Description: Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles.
Study NCT01284790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implants
Study NCT02902094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloons
Study NCT02902094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non drug eluting balloons
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Study NCT00253708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage therapy
Study NCT02480530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Feedback
Description: Patient gets feedback reports on adherence weekly.
Study NCT02480530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback Friend
Description: In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
Study NCT03850821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Social Mechanisms Intervention
Description: The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day.
Study NCT02972827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM/FloTrac
Description: Use of noninvasive cardiac output and minimally invasive cardiac output monitors
Study NCT02972827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid Fluid Challenge
Description: 500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
Study NCT02658448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg